AB Science was founded in 2001 by a team of researchers, clinicians and entrepreneurs who have dedicated their lives to discover key mechanisms in life science and develop new drugs targeting these mechanisms to dramatically change the life of patients in the most unmet medical needs. We are innovators and scientific entrepreneurs in the field of life science.
Our group is specialized in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical needs in the field of cancers, chronic inflammatory diseases and neurological degenerative disorders.
We remain fully committed in meeting our objectives and we are very confident in our capacities to develop leading treatments that will dramatically change the lives of the patients.
May 5 (Reuters) -The FDA just approved a new drug for ALS.
It's the first new drug to treat the neurodegenerative disease to get US approval in 22 years.
The drug, known chemically as edaravone, is already sold by Japanese pharmaceutical company Mitsubishi Tanabe Pharma Corp…